Most Read Articles
Dr. Rose Zhao-Wei Ting, 16 Nov 2016
A 55-year-old man presented with almost one year history of heat intolerance, mild palpitation and significant weight loss. Free T3 and T4 were elevated with normal TSH. Patient had suboptimal response to carbimazole therapy.
Yao-Hua Law, PhD, 15 Dec 2016
The genomics of cancer patients affect their responses to therapies. Some genomic alterations in cancer genes are better treated with targeted therapies, and physicians informed by genomic profiles of their patients can better decide on optimal treatments. Next-generation sequencing (NGS) technology has facilitated rapid and inexpensive gene sequencing for clinical use. This article discusses NGS applications for cancer management, focusing on comprehensive genomic profiling (CGP).
14 Mar 2017
Over 20 leading surgical and medical oncologists from Singapore attended a dinner meeting on the Neoadjuvant treatment of early breast cancer (eBC). Co-chaired by Dr Veronique Tan (National Cancer Centre, Singapore) and Dr Elaine Lim (National Cancer Centre, Singapore), the meeting served as a platform to discuss the role of neoadjuvant therapy in eBC management. Guest speakers, Professor J. Michael Dixon OBE (Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom) and Dr Rebecca Dent (National Cancer Centre, Singapore) shared their perspectives on the benefits of neoadjuvant therapy in different BC subtypes.

Acupuncture effectively reduces joint pain among breast cancer patients on aromatase inhibitors

Dr. Joseph Delano Fule Robles
15 Dec 2017
Dr Dawn Hershman © MedMeetingImages/Todd Buchanan 2017

A recent study presented at the 2017 San Antonio Breast Cancer Symposium (SABCS) showed that acupuncture is effective in reducing aromatase inhibitorinduced joint symptoms among breast cancer patients. 

The multicentre, randomized controlled trial, which included 226 postmenopausal women with early-stage breast cancer randomized to receive either true acupuncture (n=110), sham acupuncture (n=59) or no treatment (n=57), revealed significant reduction in the “worst pain” score at 6 weeks. [SABCS 2017, abstract GS4-04]

The 6-week mean Brief Pain Inventory (BPI-WP) score was 0.92 points lower in the true acupuncture group vs the sham acupuncture group, and 0.96 points lower vs the no treatment group (both p=0.01)

More patients experienced improvement in BPI-WP scores in the true acupuncture group vs the sham acupuncture and no treatment groups (58 vs 33 and 31 percent, respectively).

"We have shown consistently, with multiple measures assessing pain and stiffness, that true acupuncture generated better outcomes and could possibly increase aromatase inhibitor adherence and subsequent breast cancer outcomes,” said investigator Dr Dawn Hershman of the Herbert Irving Comprehensive Cancer Center, Columbia University, New York City, US.

Patients who received true acupuncture had improved symptoms compared with sham acupuncture at week 6 according to all other BPI pain measures (average pain, p=0.04; pain interference, p=0.02; pain severity, p=0.05; worst stiffness, p=0.02). 

Patients randomized to receive true acupuncture also experienced generally improved symptoms of the hips, knees and hands compared with the other two groups at week 6 and at week 12, as measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and the Modified Score for the Assessment of Chronic Rheumatoid Affections of the Hands (M-SACRAH) (p<0.05).

“Improvements in worst pain scores were maintained to week 24, which indicates the durability of the effect,” Hershman added.

With regard to adverse events, more patients in the true acupuncture group experienced minor bruising vs the sham acupuncture group (47 vs 25 percent; p=0.01).

Patients in the study had been taking aromatase inhibitors for at least 30 days, with a BPI-WP worst pain score of ≥3 out of 10. They underwent two treatment sessions per week for 6 weeks, followed by one treatment session per week for the next 6 weeks. The patients were then followed up for another 12 weeks.

"This is great news in that women are often looking for nonpharmacologic ways to decrease the musculoskeletal symptoms they might experience with aromatase inhibitors, which are very effective in the treatment of hormone-sensitive breast cancer,” commented discussant Dr Ann Partridge of the Dana Farber Cancer Institute, Boston, Massachusetts, US.

“However, it is not known how long the treatment effect would last beyond the 24-week study period, and there are no data as to whether maintenance or booster sessions might be needed. This is important because aromatase inhibitors are usually prescribed for at least 5 years,” she added. 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Dr. Rose Zhao-Wei Ting, 16 Nov 2016
A 55-year-old man presented with almost one year history of heat intolerance, mild palpitation and significant weight loss. Free T3 and T4 were elevated with normal TSH. Patient had suboptimal response to carbimazole therapy.
Yao-Hua Law, PhD, 15 Dec 2016
The genomics of cancer patients affect their responses to therapies. Some genomic alterations in cancer genes are better treated with targeted therapies, and physicians informed by genomic profiles of their patients can better decide on optimal treatments. Next-generation sequencing (NGS) technology has facilitated rapid and inexpensive gene sequencing for clinical use. This article discusses NGS applications for cancer management, focusing on comprehensive genomic profiling (CGP).
14 Mar 2017
Over 20 leading surgical and medical oncologists from Singapore attended a dinner meeting on the Neoadjuvant treatment of early breast cancer (eBC). Co-chaired by Dr Veronique Tan (National Cancer Centre, Singapore) and Dr Elaine Lim (National Cancer Centre, Singapore), the meeting served as a platform to discuss the role of neoadjuvant therapy in eBC management. Guest speakers, Professor J. Michael Dixon OBE (Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom) and Dr Rebecca Dent (National Cancer Centre, Singapore) shared their perspectives on the benefits of neoadjuvant therapy in different BC subtypes.